Overview

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Status:
Completed

Trial end date:
2019-04-26

Target enrollment:

Participant gender:

Summary

0116-ASG REMETY is a multicenter, open-label, non-randomized, dose-escalation Phase I study evaluating the safety and anti-tumor activity of TAS-102 administered in combination with Regorafenib in patients with metastatic colorectal cancer.

Phase:

Phase 1

Details

Lead Sponsor:

AIO-Studien-gGmbH

Collaborators:

Bayer
Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH

Treatments:

Trifluridine